Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma
- PMID: 21900389
- PMCID: PMC3575079
- DOI: 10.1158/1078-0432.CCR-11-1595
Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma
Abstract
Ipilimumab (MDX-010, Yervoy; Bristol-Myers Squibb), a fully human monoclonal antibody against CTL antigen 4 (CTLA-4), was recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of metastatic melanoma. In both early- and late-phase trials, ipilimumab has shown consistent activity against melanoma. For example, in a randomized phase III trial that enrolled patients with previously treated metastatic disease, ipilimumab, with or without a peptide vaccine, improved overall survival: Median overall survival was 10.1 and 10.0 months in the ipilimumab and ipilimumab plus vaccine arms, respectively, versus 6.4 months in the vaccine-alone group (hazard ratio, 0.68; P ≤ 0.003). Serious (grade 3-5) immune-related adverse events occurred in 10% to 15% of patients. Thus, although it provides a clear survival benefit, ipilimumab administration requires careful patient monitoring and sometimes necessitates treatment with immune-suppressive therapy. Here, we review the mechanism of action, preclinical data, and multiple clinical trials that led to FDA approval of ipilimumab for metastatic melanoma.
Figures
Similar articles
-
Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer.Pharmacol Res. 2012 Jan;65(1):9-22. doi: 10.1016/j.phrs.2011.09.002. Epub 2011 Sep 10. Pharmacol Res. 2012. PMID: 21930211 Review.
-
Ipilimumab in the treatment of metastatic melanoma: a summary of recent studies.Tumori. 2013 Nov-Dec;99(6):302e-5e. doi: 10.1700/1390.15474. Tumori. 2013. PMID: 24503809
-
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.N Engl J Med. 2015 Jul 2;373(1):23-34. doi: 10.1056/NEJMoa1504030. Epub 2015 May 31. N Engl J Med. 2015. PMID: 26027431 Free PMC article. Clinical Trial.
-
Improved survival with ipilimumab in patients with metastatic melanoma.N Engl J Med. 2010 Aug 19;363(8):711-23. doi: 10.1056/NEJMoa1003466. Epub 2010 Jun 5. N Engl J Med. 2010. PMID: 20525992 Free PMC article. Clinical Trial.
-
Profile of ipilimumab and its role in the treatment of metastatic melanoma.Drug Des Devel Ther. 2011;5:489-95. doi: 10.2147/DDDT.S10945. Epub 2011 Dec 16. Drug Des Devel Ther. 2011. PMID: 22267918 Free PMC article. Review.
Cited by
-
Exploring potential roles of long non-coding RNAs in cancer immunotherapy: a comprehensive review.Front Immunol. 2024 Aug 27;15:1446937. doi: 10.3389/fimmu.2024.1446937. eCollection 2024. Front Immunol. 2024. PMID: 39257589 Free PMC article. Review.
-
Tumor-Homing Antibody-Cytokine Fusions for Cancer Therapy.Onco Targets Ther. 2024 Aug 29;17:697-715. doi: 10.2147/OTT.S480787. eCollection 2024. Onco Targets Ther. 2024. PMID: 39224695 Free PMC article. Review.
-
A bibliometric insight into nanomaterials in vaccine: trends, collaborations, and future avenues.Front Immunol. 2024 Aug 12;15:1420216. doi: 10.3389/fimmu.2024.1420216. eCollection 2024. Front Immunol. 2024. PMID: 39188723 Free PMC article.
-
Lysine methylation modifications in tumor immunomodulation and immunotherapy: regulatory mechanisms and perspectives.Biomark Res. 2024 Jul 30;12(1):74. doi: 10.1186/s40364-024-00621-w. Biomark Res. 2024. PMID: 39080807 Free PMC article. Review.
-
Neoantigen Identification and Dendritic Cell-Based Vaccines for Lung Cancer Immunotherapy.Vaccines (Basel). 2024 May 5;12(5):498. doi: 10.3390/vaccines12050498. Vaccines (Basel). 2024. PMID: 38793749 Free PMC article. Review.
References
-
- Brunet JF, Denizot F, Luciani MF, Roux-Dosseto M, Suzan M, Mattei MG, et al. A new member of the immunoglobulin superfamily—CTLA-4. Nature. 1987;328:267–70. - PubMed
-
- Thompson CB, Allison JP. The emerging role of CTLA-4 as an immune attenuator. Immunity. 1997;7:445–50. - PubMed
-
- Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahinian A, Lee KP, et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science. 1995;270:985–8. - PubMed
-
- Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity. 1995;3:541–7. - PubMed
-
- Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996;271:1734–6. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical